title: Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation.
abstract: BACKGROUND
  Scleromyxedema is a rare chronic fibromucinous disorder that can have devastating clinical manifestations, including sclerosis of the skin with progressive pharyngeal and upper airway involvement, resulting in high mortality due to respiratory complications. Herein we describe a novel therapeutic approach. Because autologous hematopoietic stem cell transplantation is effective in other plasma cell proliferative disorders, it may be effective in this setting.
  
  
  METHODS
  We retrospectively evaluated 6 patients who were offered high-dose chemotherapy with stem cell rescue as treatment for scleromyxedema. One heavily pretreated patient was unable to mobilize stem cells. The remaining 5 patients mobilized stem cells and underwent successful transplantation. There was no treatment-related mortality. Hematologic responses were seen in 4 patients, including 2 complete remissions and 2 partial remissions, and all 4 had improvement in extracutaneous manifestations. All 4 patients subsequently had relapse of the monoclonal protein, and 3 developed skin relapses at 14, 37, and 45 months.
  
  
  CONCLUSIONS
  High-dose chemotherapy with stem cell rescue is feasible for patients with scleromyxedema and, although not curative, offers durable remission in most patients. This therapy should be considered before treatment with alkylating agents or other treatments that could adversely affect the ability to collect stem cells.
authors.affiliation: Division of Hematology and Internal Medicine, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA. lacy.martha@mayo.edu
authors.forename: Martha Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: William J
authors.initials: WJ
authors.lastname: Hogan
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: Suzanne
authors.initials: S
authors.lastname: Hayman
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: Arnold L
authors.initials: AL
authors.lastname: Schroeter
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D017512:Lichenoid Eruptions / Q000601:surgery; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009230:Myxedema / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D045745:Scleroderma, Limited / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D008558:Melphalan